Dr. Edwards, you have been both a lecturer and a researcher. What made you ‘come over to the dark side’ and become a manager? I do…
In Conversation
“ Lilly has invested over one billion EUR in its Kinsale site to date—including a recent 330 million EUR expansion that positions Ireland as a key location… ”
Could you tell our readers who are not familiar with the Biopark with an introduction of the Biopark and its institutes? The BioPark of Charleroi Brussels…
The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local generics…
Business & Decision Life Science was founded back in 2007, although that department existed within the group’s structure long before that. Could you highlight the reasons…
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the…
Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the…
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian…
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for…
Can you give our readers a snapshot of Austroplant’s scope of activities and its structure in Austria and the central European market? Austroplant/Dr Peithner belongs to…
Dr Prchla, you have been heading Merck’s Austrian subsidiary over the past eighteen months. What do you see as the key strengths of your company today?…
